{"nctId":"NCT00350779","briefTitle":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","startDateStruct":{"date":"2006-06-12","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":262,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin","Drug: rosiglitazone","Drug: metformin","Drug: glipizide"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: rosiglitazone","Drug: metformin","Drug: glipizide"]}],"interventions":[{"name":"sitagliptin","otherNames":["Januvia"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"rosiglitazone","otherNames":["Avandia"]},{"name":"metformin","otherNames":[]},{"name":"glipizide","otherNames":["Glucotrol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is inadequately controlled while taking two oral antidiabetic medications\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient required insulin therapy within the prior 3 months\n* Patient has been taking Byetta (R) (exenatide) within the prior 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18","description":"HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":null},{"groupId":"OG001","value":"-0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (Fasting Plasma Glucose) at Week 18","description":"Change from baseline at Week 18 is defined as Week 18 minus Week 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.7","spread":null},{"groupId":"OG001","value":"-11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 18","description":"Change from baseline at Week 18 is defined as Week 18 minus Week 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.9","spread":null},{"groupId":"OG001","value":"-22.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54","description":"HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":null},{"groupId":"OG001","value":"-0.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54","description":"Change from baseline at Week 54 is defined as Week 54 minus Week 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.0","spread":null},{"groupId":"OG001","value":"-10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54","description":"Change from baseline at Week 54 is defined as Week 54 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.7","spread":null},{"groupId":"OG001","value":"-16.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Any Infections And Infestations","Upper Respiratory Tract Infection","Nasopharyngitis","Any Nervous System Disorders","Any General Disorders And Administration Site Conditions"]}}}